Key facts
- Cibus Therapeutics’s last known valuation is $18.0M (Mar 2025).
- It has raised $6.3M; the latest was Seed Round ($6.3M) in Mar 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Cibus Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cibus Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cibus Therapeutics
Developer of small-molecule therapies designed to treat gastrointestinal inflammatory diseases. The company specializes in targeted treatments that address specific inflammatory pathways associated with chronic pancreatitis and ulcerative colitis, enabling patients and clinicians to manage GI conditions using precision medicine approaches.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2025
- Website
- cibustherapeutics.com/
- Ownership
- Privately Held (backing)
Cibus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cibus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cibus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.